NLS Pharmaceutics (NLSPW) Stock Price, News & Analysis

Company Overview

NLS Pharmaceutics Ltd. is a clinical-stage specialty pharmaceutical company headquartered in Zurich, Switzerland. The company focuses on the development and commercialization of innovative drug delivery systems that enhance the performance of existing small-molecule and peptide therapies. NLS Pharmaceutics employs a proprietary lipid nanoparticle platform to formulate products aimed at improving solubility, bioavailability and patient adherence.

Through its core technology, NLS Pharmaceutics creates advanced formulations designed for central nervous system, dermatology and ophthalmology indications. By leveraging controlled-release and targeted-delivery approaches, the company seeks to reduce dosing frequency, minimize side effects and optimize therapeutic profiles. Its research and development activities encompass preclinical testing, formulation optimization and human clinical trials.

The company’s pipeline includes multiple clinical-stage candidates, among them proprietary formulations of established compounds for migraine prevention, sleep disorders and other CNS indications. NLS Pharmaceutics collaborates with academic institutions and commercial partners to advance its product candidates through regulatory pathways in Europe, North America and additional markets. By combining novel delivery solutions with well-characterized active pharmaceutical ingredients, the company aims to bring differentiated therapies to patients and healthcare providers globally.

Key Stats

• Today's Range: $0.01 to $0.02
• 50-Day Range: $0.01 to $0.03
• 52-Week Range: $0.00 to $0.07
• Volume: 130,055 shs
• Average Volume: 49,507 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NLSPW
• CIK: 1783036
• Web: N/A
• Phone: 41-44-512-21-50
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A